Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Use of α2δ Ligands for Restless Legs Syndrome/Willis Ekbom Disease.

Faulkner MA.

CNS Drugs. 2018 Feb;32(2):149-159. doi: 10.1007/s40263-018-0502-z. Review.

PMID:
29480463
2.

Spotlight on perampanel in the management of seizures: design, development and an update on place in therapy.

Faulkner MA.

Drug Des Devel Ther. 2017 Oct 4;11:2921-2930. doi: 10.2147/DDDT.S122404. eCollection 2017. Review.

3.

Comprehensive overview: efficacy, tolerability, and cost-effectiveness of clobazam in Lennox-Gastaut syndrome.

Faulkner MA.

Ther Clin Risk Manag. 2015 Jun 8;11:905-14. doi: 10.2147/TCRM.S55930. eCollection 2015. Review.

4.

Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson's disease.

Faulkner MA.

Expert Opin Drug Saf. 2014 Aug;13(8):1055-69. doi: 10.1517/14740338.2014.931369. Epub 2014 Jun 24. Review.

PMID:
24962891
5.

Perampanel: a new agent for adjunctive treatment of partial seizures.

Faulkner MA.

Am J Health Syst Pharm. 2014 Feb 1;71(3):191-8. doi: 10.2146/ajhp130203. Review.

PMID:
24429011
6.

Comparison of cardiovascular risk calculation tools in pharmacy practice.

White ND, Lenz TL, Skrabal MZ, Faulkner MA, Skradski JJ, Southard LA, Popken DE.

J Am Pharm Assoc (2003). 2013 Jul-Aug;53(4):408-13. doi: 10.1331/JAPhA.2013.12181.

PMID:
23892814
7.

Safety profile of two novel antiepileptic agents approved for the treatment of refractory partial seizures: ezogabine (retigabine) and perampanel.

Faulkner MA, Burke RA.

Expert Opin Drug Saf. 2013 Nov;12(6):847-55. doi: 10.1517/14740338.2013.823399. Epub 2013 Jul 25. Review.

PMID:
23883095
8.

Neurogenetic disorders and treatment of associated seizures.

Faulkner MA, Singh SP.

Pharmacotherapy. 2013 Mar;33(3):330-43. doi: 10.1002/phar.1201. Epub 2013 Feb 11. Review.

PMID:
23400943
9.

Using employee experts to offer an interprofessional diabetes risk reduction program to fellow employees.

Lenz TL, Gillespie ND, Skrabal MZ, Faulkner MA, Skradski JJ, Ferguson LA, Pagenkemper JJ, Moore GA, Jorgensen D.

J Interprof Care. 2013 Mar;27(2):197-9. doi: 10.3109/13561820.2012.721816. Epub 2012 Sep 7.

PMID:
22957897
10.

Review of the treatment of restless legs syndrome: focus on gabapentin enacarbil.

Burke RA, Faulkner MA.

J Cent Nerv Syst Dis. 2012 Sep 17;4:147-56. doi: 10.4137/JCNSD.S9107. Print 2012.

11.

Gabapentin enacarbil for the treatment of restless legs syndrome (RLS).

Burke RA, Faulkner MA.

Expert Opin Pharmacother. 2011 Dec;12(18):2905-14. doi: 10.1517/14656566.2011.635645. Epub 2011 Nov 14. Review.

PMID:
22077768
12.

Treatment options for refractory and difficult to treat seizures: focus on vigabatrin.

Tolman JA, Faulkner MA.

Ther Clin Risk Manag. 2011;7:367-75. doi: 10.2147/TCRM.S8519. Epub 2011 Sep 1.

13.

Safety and efficacy of vigabatrin for the treatment of infantile spasms.

Faulkner MA, Tolman JA.

J Cent Nerv Syst Dis. 2011 Sep 14;3:199-207. doi: 10.4137/JCNSD.S6371. Print 2011.

14.

Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval.

Tolman JA, Faulkner MA.

Expert Opin Pharmacother. 2009 Dec;10(18):3077-89. doi: 10.1517/14656560903451690. Review.

PMID:
19954276
15.

Smoking cessation: an economic analysis and review of varenicline.

Faulkner MA.

Clinicoecon Outcomes Res. 2009;1:25-34. Epub 2009 Jun 24.

16.

Prevalence, treatment, and control of hypertension in residents of skilled nursing facilities.

Coover KL, Ryan-Haddad A, Faulkner MA, Hilleman DE.

Consult Pharm. 2008 Apr;23(4):317-23.

PMID:
18454588
17.

Cost-effectiveness of smoking cessation and the implications for COPD.

Faulkner MA, Lenz TL, Stading JA.

Int J Chron Obstruct Pulmon Dis. 2006;1(3):279-87. Review.

18.

Effects of prednisone on the International Normalized Ratio.

Stading JA, Chock A, Faulkner MA, Skrabal MZ.

Am J Health Syst Pharm. 2006 Dec 1;63(23):2354-6. Erratum in: Am J Health Syst Pharm. 2007 Jan 15;64(2):130. Chock, Alan [added]; Faulkner, Michele A [added]; Skrabal, Maryann Z [added].

PMID:
17106008
19.

Osteoporosis in long-term care residents with multiple sclerosis.

Faulkner MA, Ryan-Haddad AM, Lenz TL, Degner K.

Consult Pharm. 2005 Feb;20(2):128-36.

PMID:
16548616
20.

Development of diabetes after gatifloxacin therapy.

Stading JA, Chock AW, Skrabal MZ, Faulkner MA.

Am J Health Syst Pharm. 2005 Nov 1;62(21):2293-5. No abstract available.

PMID:
16239422
21.

Cost of a pharmacist-directed intervention to increase treatment of hypercholesterolemia.

Hilleman DE, Faulkner MA, Monaghan MS.

Pharmacotherapy. 2004 Aug;24(8):1077-83. Review.

PMID:
15338855
22.

Potential interactions between exercise and drug therapy.

Lenz TL, Lenz NJ, Faulkner MA.

Sports Med. 2004;34(5):293-306. Review.

PMID:
15107008
23.

Pharmacologic treatment of chronic obstructive pulmonary disease: past, present, and future.

Faulkner MA, Hilleman DE.

Pharmacotherapy. 2003 Oct;23(10):1300-15. Review.

PMID:
14594347
24.

Gabapentin for the treatment of tremor.

Faulkner MA, Bertoni JM, Lenz TL.

Ann Pharmacother. 2003 Feb;37(2):282-6. Review.

PMID:
12549962
25.

The economic impact of chronic obstructive pulmonary disease.

Faulkner MA, Hilleman DE.

Expert Opin Pharmacother. 2002 Mar;3(3):219-28. Review.

PMID:
11866672
26.

Seven cases of interaction between warfarin and cyclooxygenase-2 inhibitors.

Stading JA, Skrabal MZ, Faulkner MA.

Am J Health Syst Pharm. 2001 Nov 1;58(21):2076-80. Review. No abstract available.

PMID:
11715832
27.

Potential influence of timing of low-density lipoprotein cholesterol evaluation in patients with acute coronary syndrome.

Faulkner MA, Hilleman DE, Destache CJ, Mooss AN.

Pharmacotherapy. 2001 Sep;21(9):1055-60.

PMID:
11560195
28.

Amlodipine/benazepril: fixed dose combination therapy for hypertension.

Faulkner MA, Hilleman DE.

Expert Opin Pharmacother. 2001 Jan;2(1):165-78. Review.

PMID:
11336577
30.

A gas chromatographic mass spectrometric chemical ionization assay for haloperidol with selected ion monitoring.

Hornbeck CL, Griffiths JC, Neborsky RJ, Faulkner MA.

Biomed Mass Spectrom. 1979 Oct;6(10):427-30.

PMID:
526559
31.

The revolving-door alcoholic. An impasse in the treatment of the chronic alcoholic.

Gallant DM, Bishop MP, Mouledoux A, Faulkner MA, Brisolara A, Swanson WA.

Arch Gen Psychiatry. 1973 May;28(5):633-5. No abstract available.

PMID:
4700677
32.

Cyclic nucleotide regulation of gastric acid secretion.

Charters AC, Chandler JG, Flamant YM, Faulkner MA, Orloff MJ.

Surg Forum. 1973;24:361-3. No abstract available.

PMID:
4377035
33.

A comparative evaluation of compulsory (group therapy and-or antabuse) and voluntary treatment of the chronic alcoholic munciple court offender.

Gallant DM, Bishop MP, Faulkner MA, Simpson L, Cooper A, Lathrop D, Brisolara AM, Bossetta JR.

Psychosomatics. 1968 Nov-Dec;9(6):306-10. No abstract available.

PMID:
5725612
34.

The value of a "first contact" group intake session in an alcoholism outpatient clinic: statistical confirmation.

Gallant DM, Bishop MP, Stoy B, Faulkner MA, Paternostro L.

Psychosomatics. 1966 Nov-Dec;7(6):349-52. No abstract available.

PMID:
5979973

Supplemental Content

Loading ...
Support Center